

07-12-01

RECEIVED
U.S. PATENT & TRADEMARK OFFICE
TELEFAX CENTER
1600/2900
25 JUL 17 2001

Docket No. 01723326



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent Application of:)
Jeffrey Owen Phillips)
Serial No.: 09/481,207)
Filed: January 11, 2000)
For: Novel Substituted)
Benzimidazole Dosage Forms)
and Method of Using Same)
Examiner: Fan, J.)
Group Art Unit: 1625)

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" mailing label number
EL692808565US

Date of Deposit: July 11, 2001
I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" under
37 CFR 1.10 on the date indicated above and is
addressed to U.S. Patent and Trademark Office,
Washington, DC 20231

Tim Hubalik
(typed or printed name of person mailing paper
or fee)

(signature of person mailing paper or fee)

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Enclosed herewith is the Information Disclosure Statement for the above-captioned case.

Also enclosed are:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. One (1) copy of 333 references (Nos. 1-333, except Nos. 64-65, 88, 99, 108-110, 114, 118, 120, 132, 136, 139-188, 191, 193-196, 200-201 and 205-207). Please note that the missing copies will be supplied in the next several weeks, and that all of the references are being hand-delivered to the Examiner per her request;
4. Check in the amount of \$180; and
5. Return-receipt postcard.

The Commissioner is hereby authorized to charge any additional filing fees required under Rule 1.17 concerning this transaction, or to credit any overpayment to Deposit Account 13-0019. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

THE CURATORS OF THE
UNIVERSITY OF MISSOURI

By: MAYER, BROWN & PLATT

By: 
Joseph A. Mahoney (Reg. No. 38,956)

Dated: July 11, 2001

MAYER, BROWN & PLATT
P.O. Box 2828
Chicago, IL 60609-2828
(312) 701-8979



Docket No. 01723326

TECH CENTER 1600/2900

JUL 17 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of:)
Jeffrey Owen Phillips)
Serial No.: 09/481,207) Examiner: Fan, J.
Filed: January 11, 2000) Group Art Unit: 1625
For: Novel Substituted Benzimidazole)
Dosage Forms and Method of)
Using Same)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

The following information is submitted pursuant to 37 CFR §§ 1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR § 1.56(a). This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§ 1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR § 1.56(a) exists.

Applicant submits herewith Form PTO 1449 listing the references cited in this Information Disclosure Statement. Applicant respectfully requests that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicant.

07/16/2001 YPOLITE1 00000066 09481207

01 FC:126

180.00 0P

Please note that this is Applicant's second Information Disclosure Statement submitted in this case. Applicant understands from the Examiner that Applicant's previous filing of February 28, 2001, which included 120 references, has never been delivered to the Examiner and is assumed to be lost by the PTO since Applicant does have confirmation of its receipt by the PTO. In addition, the Examiner has explained that the Information Disclosure Statement submitted with the parent application Ser. No. 08/680,376, now U.S. Pat. No. 5,840,737, cannot be located by the PTO. Consequently, the Examiner has asked that Applicant resubmit all such references, along with any new references.

Further, due to the large number of references submitted, the Examiner has requested that Applicant identify the most pertinent ones and highlight the relevant sections of the same. Applicant has attempted to comply with this request. However, Applicant's action to comply is not to be construed as an admission that such identified references are prior art, or that they are more or less pertinent than any of the other references because reasonable minds could differ as to what is pertinent.


Please also note that Applicant is in the process of obtaining several of the references and will be submitting these along with the corresponding numbered tabs to be placed into the tabbed notebooks submitted to the Examiner herewith. All references are being hand-delivered to the Examiner pursuant to her request.

This Information Disclosure Statement is being filed after the first office action on the merits. Accordingly, Applicant encloses the fee of \$180.00 required under 37 CFR § 1.17(p). Should there be any additional fees required, the Commissioner is authorized to charge Deposit Account No. 13-0019.

Respectfully submitted,

THE CURATORS OF THE
UNIVERSITY OF MISSOURI

By: MAYER, BROWN & PLATT

By: 
Joseph A. Mahoney (Reg. No. 38,956)

Dated: July 11, 2001

MAYER, BROWN & PLATT
P.O. Box 2828
Chicago, IL 60609-2828
(312) 701-8979

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT								APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))								FILING DATE January 11, 2000	GROUP 1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
1.	4	0	4	5	5	6	4	08/30/77	Berntsson, et al.			
2.	4	1	8	2	7	6	6	01/08/80	Krasso, et al.			
3.	4	2	5	5	4	3	1	03/10/81	Junggren, et al.			
4.	4	3	3	7	2	5	7	06/29/82	Junggren, et al.			
5.	4	4	7	2	4	0	9	09/18/84	Senn-Bilfinger			
6.	4	5	4	4	7	5	0	10/01/85	Brandstrom, et al.			
7.	4	6	2	0	0	0	8	10/28/86	Brandstrom, et al.			
8.	4	6	3	6	4	9	9	01/13/87	Brandstrom, et al.			
9.	4	7	2	5	6	9	1	02/16/88	Brandstrom, et al.			
10.	4	7	3	8	9	7	4	04/19/88	Brandstrom, et al.			
11.	4	7	8	6	5	0	5	11/22/88	Lovgren, et al.			
12.	4	8	5	3	2	3	0	08/01/89	Lovgren, et al.			
13.	5	0	0	8	2	7	8	04/16/91	Brandstrom, et al.			
14.	5	0	1	3	7	4	3	05/07/91	Iwahi, et al.			
15.	5	0	1	9	5	8	4	05/28/91	Brandstrom, et al.			
16.	5	0	2	5	0	2	4	06/18/91	Brandstrom, et al.			
17.	5	0	3	9	8	0	6	08/13/91	Brandstrom, et al.			
18.	5	0	4	5	3	2	1	09/03/91	Makino, et al.			
19.	5	0	7	5	3	2	3	12/24/91	Fain, et al.			
20.	5	0	9	3	1	3	2	03/03/92	Makino, et al.			
21.	5	0	9	3	3	4	2	03/03/92	Tomoi, et al.			
22.	5	1	0	6	8	6	2	04/21/92	Briving, et al.			
23.	5	2	1	5	9	7	4	06/01/93	Alminger, et al.			
24.	5	2	1	9	8	7	0	06/15/93	Kim			
25.	5	2	3	2	7	0	6	08/03/93	Coll			
26.	5	3	7	4	7	3	0	12/20/94	Slemon, et al.			
27.	5	3	8	5	7	3	9	01/31/95	Debregeas, et al.			
28.	5	3	8	6	0	3	2	01/31/95	Brandstrom			
29.	5	3	9	1	7	5	2	02/21/95	Hoerrner, et al.			
30.	5	3	9	5	3	2	3	03/07/95	Berglund			
31.	5	3	9	9	7	0	0	03/21/95	Min, et al.			
32.	5	4	1	7	9	8	0	05/23/95	Goldman, et al.			
33.	5	4	3	0	0	4	2	07/04/95	Lindberg, et al.			
34.	5	4	4	7	9	2	3	09/05/95	Castrenich, et al.			
25.	5	4	7	0	9	8	3	11/28/95	Slemon, et al.			
36.	5	5	8	9	4	9	1	12/31/96	Nakanishi, et al.			
37.	5	5	9	9	7	9	4	02/04/97	Eek, et al.			
38.	5	6	2	9	3	0	5	05/13/97	Eek, et al.			
39.	5	6	3	3	2	4	4	05/27/97	Eek, et al.			
40.	5	6	9	0	9	6	0	11/25/97	Bengtsson, et al.			
41.	5	6	9	3	8	1	8	12/02/97	Von Unge			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

duplicate

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE									ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT									APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))									FILING DATE January 11, 2000	GROUP 1625

U.S. PATENT DOCUMENTS

42.	5	7	1	4	5	0	4	02/03/98	Lindberg, et al.			
43.	5	7	1	4	5	0	5	02/03/98	Hasselkus			
44.	5	7	3	1	0	0	2	03/24/98	Olovson, et al.			
45.	5	7	5	3	2	6	5	05/19/98	Bergstrand, et al.			
46.	5	7	6	6	6	2	2	06/16/98	Nelson			
47.	5	7	7	6	7	6	5	07/07/98	Graham, et al.			
48.	5	8	1	4	3	3	8	09/29/98	Veronesi			
49.	5	8	1	7	3	3	8	10/06/98	Bergstrand, et al.			
50.	5	8	4	0	7	3	7	11/24/98	Phillips			
51.	5	8	7	7	1	9	2	03/02/99	Lindberg, et al.			
52.	5	8	8	3	1	0	2	03/16/99	Hamley, et al.			
53.	5	8	8	5	5	9	4	03/23/99	Nilsen, et.al.			
54.	5	9	0	0	4	2	4	05/04/99	Kallstrom, et al.			
55.	5	9	2	9	2	4	4	07/27/99	Von Unge			
56.	5	9	3	9	0	9	1	08/17/99	Eoga, et al.			
57.	5	9	4	8	7	8	9	09/07/99	Larsson, et al.			
58.	5	9	5	5	1	0	7	09/21/99	Augello, et al.			
59.	5	9	5	8	9	5	5	09/28/99	Gustavsson, et al.			
60.	5	9	6	2	0	2	2	10/05/99	Bolt, et al.			
61.	5	9	6	5	1	6	2	10/12/99	Fuisz, et al.			
62.	5	9	7	9	5	1	5	11/09/99	Olsson			
63.	6	0	1	3	2	8	1	01/11/00	Lundberg, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL		DOCUMENT NUMBER					PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
											YES	NO
64.		8	8	3	5	1		04/30/86	RO			
65.		2	1	8	9	6	9	8	11/04/87	UK		
66.		1	2	3	4	1	1	8	03/15/88	CA		
67.	0	5	1	9	4	2	2	5	08/03/93	JP/English Trans. Attached		
68.		9	4	0	0	1	1	2	01/06/94	WO		
69.		9	4	0	2	1	4	0	02/03/94	WO A1		
70.		9	5	3	2	9	5	7	12/07/95	WO A1		
71.		9	6	0	1	6	1	2	01/25/96	WO A1		
72.		9	6	0	1	6	2	2	01/25/96	WO A1		
73.		9	6	2	4	3	7	5	08/15/96	WO A1		
74.		9	7	2	5	0	3	0	07/17/97	WO A1		
75.		9	7	4	1	1	1	4	11/06/97	WO A1		
76.		9	7	4	8	3	8	0	12/24/97	WO A1		
77.		9	8	0	2	3	6	8	01/22/98	WO A1		
78.		9	8	2	8	2	9	4	07/02/98	WO A1		
79.		9	8	5	0	0	1	9	11/12/98	WO A1		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT										APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))										FILING DATE January 11, 2000	GROUP 1625

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

80.	9	8	5	3	8	0	3	12/03/98	WO A1			
81.	9	8	5	4	1	7	1	12/03/98	WO A1			
82.	9	9	0	0	3	8	0	01/07/99	WO A1			
83.	9	9	0	8	5	0	0	02/25/99	WO A2			
84.	9	9	2	5	7	1	1	05/27/99	WO A1			
85.	9	9	2	7	9	1	7	06/10/99	WO A1			
86.	9	9	2	9	3	2	0	06/17/99	WO A1			
87.	9	9	2	9	2	9	9	06/17/99	WO A1			
88.	1	9	7	5	2	8	4	3	07/01/99	DK		
89.	9	9	3	2	0	9	1	07/01/99	WO A1			
90.	9	9	3	2	0	9	3	07/01/99	WO A1			
91.	0	0	2	6	1	8	5	05/11/00	WO A2 & A3			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	92.	"Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers", Chapter 37, pp. 907-909, 1768.
	93.	"Omeprazole, An Updated Review of its Pharmacology and Therapeutic Use in Acid-Related Disorders" by D. McTavish, et al., <u>Drugs</u> , Vol. 42, No. 1, pp. 138-170 (1991).
	94.	"Omeprazole, Overview and Opinion" by S. Holt, et al., <u>Digestive Diseases and Sciences</u> , Vol. 36, No. 4, pp. 385-393 (April 1991).
	95.	"Pantoprazole, A Review of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders" by A. Fitton, et al., <u>Drugs</u> , Vol. 51, No. 3, pp. 460-482 (March 1996).
	96.	"Differential Stereoselective Pharmacokinetics of Pantoprazole, a Proton Pump Inhibitor in Extensive and Poor Metabolizers of Pantoprazole – A Preliminary Study" by M. Tanaka, et al., <u>Chirality</u> , Vol. 9, pp. 17-21 (1997).
	97.	"A Prospective Study of Simplified Omeprazole Suspension for the Prophylaxis of Stress-related Mucosal Damage" by J. Phillips, et al., <u>Critical Care Medicine</u> , Vol. 24, No. 11, pp. 1793-1800 (1996).
	98.	"A Prospective Study of Omeprazole Suspension to Prevent Clinically Significant Gastrointestinal Bleeding From Stress Ulcers in Mechanically Ventilated Trauma Patients" by M. Lasky, et al., <u>The Journal of Trauma: Injury Infection, and Critical Care</u> , Vol. 44, No. 3, pp. 527-533 (March 1998).
	99.	"Effect of Combined Administration of Lansoprazole and Sofalcone on Microvascular and Connective Tissue Regeeration After Ethanol-induced Mucosal Damage" by M. Nakamura, et al., <u>Journal of Clinical Gastroenterology</u> , Vol. 27, Supp. 1, pp. 170-77 (1998).
	100.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 [Date stamped in Howard University Library on January 13, 1995].

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))		FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

101.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in Walter Reed Army Medical Center Medical Library on January 17, 1995].
102.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in FDA Medical Library January 6, 1995].
103.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in University of Illinois on January 10, 1995].
104.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in Central DuPage Hospital Medical Library on January 10, 1995].
105.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in University of Missouri Health Sciences Library January 6, 1995].
106.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Although allegedly date stamped in St. Vincent's Hospital Medical Library on January 3, 1995, interviews of library personnel revealed that this Supplement was not received until Jan. 9, 1995, as the January 9, 1995 date is found in their computerized database.]
107.	"Lansoprazole Capsules and Amoxicillin Oral Suspension in the Treatment of Peptic Ulcer Disease" by J. Hatlebakk, et al., <u>Scand. J. Gastroenterol.</u> , Vol. 30, No. 11, pp. 1053-57 (1995).
108.	"Nicotinamide Pharmacokinetics in Humans: Effect of Gastric Acid Inhibition, Comparison of Rectal vs Oral Administration and the Use of Saliva for Drug Monitoring" by M.R. Stratford, et al. <u>J Cancer</u> , Vol. 74, No. 1, pp. 16-21 (July 1996).
109.	"Comments of the Report of 'Association' of Omeprazole with DNA by Phillips, et al." by S.P. Adams <u>Mutagenesis</u> , Vol. 7, No. 5, pp. 395-396 (September 1992).
110.	"Interaction of Omperazole with DNA in Rat Issues" by D.H. Phillips, <u>Mutagenesis</u> , Vol. 7, No. 4, pp. 277-283 (July 1992).
111.	"Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid" by R.A. Quercia, et al., <u>American Journal of Health-System Pharmacy</u> , Vol. 54, pp. 1833-1836 (August 15, 1997).
112.	"Simplified Omeprazole Solution For The Prophylaxis of Stress-Related Mucosal Damage In Critically Ill Patients", by J. Phillips, et al., <u>Critical Care Medicine</u> , Vol. 22, No. 1, p. A53 (January 1994).
113.	"Effective Gastric Acid Suppression After Oral Administration of Enteric-Coated Omeprazole Granules" by M.A. Mohiuddin, et al., <u>Digestive Diseases and Sciences</u> , Vol. 42, No. 4, pp. 715-719 (April 1997).
114.	"Endoscopic Topical Therapy for the Treatment of Helicobacter Pylori Infection" by K. Kihira, et al. <u>J Gastroenterol</u> , Vol. 31, Suppl 9, pp. 66-68 (November 1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified)	PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))		FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

115.	"Pharmacokinetic Evaluation of Omeprazole Suspension Following Oral Administration in Rats: Effect of Neutralization of Gastric Acid" by K. Watanabe, et al., <u>Acta Med Okayama</u> , Vol. 50, No. 4, pp. 219-222 (August 1996).
116.	"Pharmacokinetics of Lansoprazole in Hemodialysis Patients" by M. Karol, et al., <u>J Clin Pharmacol</u> , Vol. 35, pp. 815-820 (August 1995).
117.	"Omeprazole: Pharmacokinetics and Metabolism in Man" by C. Cederberg, et al., <u>Scand. J. Gastroenterol.</u> , Vol. 24, Suppl. 166, pp. 33-40 (1989).
118.	"Synthesis and Structure-Activity Relationships of Substituted 2-[2-imidazolylsulfinyl)methyl] Anilines As A New Class of Gastric H+/K(+)-ATPase Inhibitors. II." by T. Yamakawa, <u>Chem Pharm Bull (Tokyo)</u> , Vol. 40, No. 3, pp. 675-682 (March 1992).
119.	"Studies on (H(+)-K+)-ATPase Inhibitors of Gastric Acid Secretion. Prodrugs of 2-[2-Pyridinylmethyl]sulfinyl]benzimidazole Proton-Pump Inhibitors" by J. Sih, et al., <u>Journal of Medicinal Chemistry</u> , Vol. 34, No. 3, pp. 1049-1062 (March 1991).
120.	"Effects of Pantoprazole, A Novel H+/K+-ATPase Inhibitor, On Duodenal Ulcerogenic and Healing Responses in Rats: A Comparative Study with Omeprazole and Lansoprazole" by Takeuchi, et al., <u>J. Gastroenterol. Hepatol.</u> , Vol. 14, No. 3, p. 251-57 (1999).
121.	"Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors: Focus on Omeprazole, Lansoprazole and Pantoprazole" by T. Andersson, <u>Clin. Pharmacokinet.</u> , Vol. 31, No. 1, pp. 9-28 (July 1996).
122.	"Nasogastric Administration of Omeprazole", <u>The Australian Journal of Hospital Pharmacy</u> , Vol. 28, No. 3, pp. 174-176 (1998).
123.	"Bioavailability and Efficacy of Omeprazole Given Orally and By Nasogastric Tube" by C. Larson, et al., <u>Digestive Diseases and Sciences</u> , Vol. 41, No. 3, pp. 475-479 (March 1996).
124.	"Nasogastric Omeprazole: Effects on Gastric pH in Critically Ill Patients" by D. Balaban, et al., <u>The American Journal of Gastroenterology</u> , Vol. 92, No. 1, pp. 79-83 (1997).
125.	"Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole" by V. Sharma, <u>American Journal of Health-System Pharmacists</u> , Vol. 56, Suppl 4, pp. S18-S21(December 1, 1999).
126.	"The Stability of Simplified Lansoprazole Suspension (SLS)" by J. Phillips, et al., <u>Gastroenterology</u> , Vol. 116, No. 4, pg. G0382 (April 1999).
127.	"Effect on 24-hour Intragastric Acidity of Simplified Omeprazole Solution (SOS) Administered Via Gastrostomy", by V. Sharma, et al., <u>AJG</u> , Vol. 92, No. 9, p. 1625, Section 169 (1997).
128.	"Simplified Lansoprazole Suspension (SLS): A Proton Pump Inhibitor (PPI) In A Liquid Formulation That Works" by V. Sharma, et al., <u>AJG</u> , p. 1647, Section 153 (September 1998).
129.	"Simplified Lansoprazole Suspension – A Liquid Formulation of Lansoprazole – Effectively Suppresses Intragastric Acidity When Administered Through a Gastrostomy" by V. Sharma, et al., <u>The American Journal of Gastroenterology</u> , Vol. 94, No. 7, pp. 1813-1817 (July 1999).
130.	"The Effects on Intragastric Acidity of Per-Gastrostomy Administration of An Alkaline Suspension of Omeprazole" by V. Sharma, et al., <u>Aliment Pharmacol Ther</u> , Vol. 13, pp. 1091-1095 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FQRM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))		FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

131.	"A Multicenter, Prospective, Randomized Clinical Trial of Continuous Infusion I.V. Ranitidine vs. Omeprazole Suspension in the Prophylaxis of Stress Ulcers" by J. Phillips, et al., <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), p. A101, No. 222 (1998).
132.	"Gastrointestinal Drugs", <u>The American Medical Association Drug Evaluation</u> , Vol. 2, The American Medical Association, Chicago, 1:8 (Bennett & Dickson, eds.).
133.	"Pharmacokinetics of [¹⁴ C]Omeprazole in Patients with Liver Cirrhosis" by T. Andersson, et al., <u>Clin Pharmacokinet.</u> , Vol. 24, No. 1, pp. 71-78 (1993).
134.	"Pharmacokinetics and Bioavailability of Omeprazole After Single and Repeated Oral Administration in Healthy Subjects" by T. Andersson, et al., <u>Br. J. Clin. Pharmac.</u> , Vol. 29, pp. 557-563 (1990).
135.	"Development of An Oral Formulation of Omeprazole" by A. Pilbrant, et al., <u>Scand. J. Gastroenterol.</u> , Vol. 20, (Suppl. 108) pp. 113-120 (1985).
136.	"Pharmacokinetics of Various Single Intravenous and Oral Doses of Omeprazole" by T. Andersson, et al., <u>European Journal of Pharmacology</u> , Vol. 39, pp. 195-197 (1990).
137.	"Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers" by S. Landahl, et al., <u>Clin. Pharmacokinet.</u> , Vol. 23, No. 6, pp. 469-476 (1992).
138.	"The Pharmacokinetics of Omeprazole in Humans - A Study of Single Intravenous and Oral Doses" by C. Regardh, et al., <u>Therapeutic Drug Monitoring</u> , Vol. 12, No. 2, pp. 163-172 (1990).
139.	"Bolus or Intravenous Infusion of Rantidine: Effects on Gastric pH and Acid Secretion" by Ballesteros, et al., <u>Ann. Intern. Med.</u> , Vol. 112, pp. 334, 339 (1990).
140.	"Therapeutic Use of Omeprazole For Refractory Stress-Induced Gastric Mucosal Hemorrhage" by Barie & Hariri, <u>Critical Care Medicine</u> , Vol. 20, pp. 899-901 (1992).
141.	"Let's Agree on Terminology: Definition of Sepsis" by Bone, <u>Critical Care Medicine</u> , Vol. 19, p. 27 (1991).
142.	"Antacids vs. Sucralfate in Preventing Acute Gastrointestinal Tract Bleeding in Abdominal Aortic Surgery" by Borrero, et al., <u>Arch. Surg.</u> , Vol. 121, pp. 810-12 (1986).
143.	<u>The Pharmacologic Basis of Therapeutics</u> by Brunton, p. 907 (1990).
144.	"Central Nervous System Reactions to Histamine-2 Receptor Blockers" by Cantu & Korek, Vol. 114, pp. 1027-34 (1994).
145.	"Comparison of Acid Neutralizing and Non-acid Neutralizing Stress Ulcer Prophylaxis in Thermally Injured Patients" by Cioffi, et al., Vol. 36, pp. 541-47 (1994).
146.	"Risk Factors For Gastrointestinal Bleeding in Critically Ill Patients" by Cook, et al., Vol. 330, pp. 377-81 (1994).
147.	"Stress Ulcer Prophylaxis in the Critically Ill: A Meta Analysis" by Cook, et al., Vol. 91, pp. 519-27 (1991).
148.	"Nasocomial Pneumonia and the Role of Gastric pH: A Meta Analysis" by Cook, et al., Vol. 100, pp. 7-13 (1991).
149.	"Acute Gastrointestinal Disease After Thermal Injury: An Endoscopic Evaluation of Incidence and Natural History" by Czaja, et al., Vol. 291, pp. 925-29 (1974).
150.	"Does pH Paper Accurately Reflect Gastric pH?" by Dobkin, et al., Vol. 18, pp. 985-88 (1990).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified)	PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))		FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

151.	"Nosocomial Pneumonia in Intubated Patients Given Sucralfate As Compared With Antacids or Histamine Type 2 Blockers" by Driks et al., <u>N. Eng. J. Med.</u> , Vol. 317, pp. 1376-82 (1987).
152.	"Prospective Trial Comparing a Combination pH Probe-Nasogastric Tube With Aspirated Gastric pH" by Eisenberg, et al., <u>Critical Care Medicine</u> , Vol. 18, 1092-95 (1990).
153.	"Pneumonia and Stress Ulceration in Severely Injured Patients" by Fabian et al., Vol. 128, p. 1855 (1993).
154.	"Substituted Benzimidazoles Inhibit Gastric Acid Secretions by Blocking H+/K+-ATPase" by Fellenius, et al., <u>Nature</u> , Vol. 290, pp. 159-61 (1981).
155.	"Predictive Value of Intramural pH and Other Risk Factors For Massive Bleeding From Stress Ulceration" by Fiddian-Green, et al., <u>Gastroenterology</u> , Vol. 8, pp. 613-20 (1983).
156.	"Function and Structure of Parietal Cells After H+/K+-ATPase Blockade" by Fryklund, et al., <u>Am. J. Physiol.</u> , Vol. 254, pp. G399-407 (1988).
157.	"Thrombocytopenia Associated with Hypersensitivity to Rantidine: Possible Cross-Reactivity" by Gafter, et al., Vol. 64, pp. 560-62 (1989).
158.	"CDC Definitions for Nosocomial Infections" by Garner, et al., <u>Am. J. Infect. Control</u> , Vol. 16, pp. 128-40 (1988).
159.	"Intragastric pH Measurement Using a Novel Disposable Sensor" by Heath, et al., <u>Intes. Care Med.</u> , Vol. 14, pp. 232-35 (1988).
160.	"Effect of Intravenous Infusion of Omeprazole and Rantidine on Twenty-Four-Hour Intragastric pH" by Kollerich, et al., Vol. 56, pp. 25-30 (1995).
161.	"Prevention of Upper Gastrointestinal Bleeding in Long Term Ventilated Patients" by Laggner, et al., <u>Am. J. Med.</u> , Vol. 86, Suppl. 6A, pp. 81-84 (1989).
162.	"Gastric Response to Severe Head Injury" by Larson, et al., <u>Am. J. Surg.</u> , Vol. 147, pp. 97-105 (1984).
163.	"Pathogenesis, Diagnosis and Treatment of Acute Gastric Mucosa Lesions" by Marrone & Silen, <u>Clin. Gastroenterol.</u> , Vol. 13, pp. 635-50 (1984).
164.	"Continuous Intravenous Cimetidine Decreases Stress-Related Upper Gastrointestinal Hemorrhage" by Martin, et al., <u>Critical Care Medicine</u> , Vol. 21, pp. 19-39 (1993).
165.	"Evaluation of Various Techniques to Monitor Intragastric pH" by Meiners et al., <u>Arch. Surg.</u> , Vol. 117, pp. 288-91 (1982).
166.	"Electrolyte and Acid-base Disorders" by Oh & Carroll, <u>The Pharmacologic Approach to the Critically Ill Patient</u> , pp. 966-67 (Chernow, B. ed. 1994).
167.	"Control of Gastric pH With Cimetidine Boluses Versus Primed Infusions" by Ostro et al., <u>Gastroenterology</u> , Vol. 89, pp. 532-37 (1985).
168.	"Cimetidine for Prevention and Treatment of Gastroesophageal Reflux Disease in Patients" by Peura & Johnson, <u>Ann. Intern. Med.</u> , Vol. 103, pp. 173-177 (1985).
169.	"Occurrence of Nosocomial Pneumonia in Mechanically Ventilated Trauma Patients" by Pickworth, et al., <u>Critical Care Medicine</u> , Vol. 12, pp. 1856-62 (1993).
170.	"Methods of Prophylaxis in Stress Ulcer Disease" by Priebe & Skillman, <u>World J. Surg.</u> , Vol. 5, pp. 223-33 (1981).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

171.	"Nasocomial Pneumonia During Stress Ulcer Prophylaxis With Cimetidine and Sucralfate" by Ryan, et al., <u>Arch. Surg.</u> , Vol. 128, pp. 1353-57 (1993).
172.	"Clinically Important Adverse Effects and Drug Interactions With H2-receptor Antagonists: An Update" by Sax, <u>Pharmacotherapy</u> , Vol. 7, pp. 110S-115S (1987).
173.	"Stress Ulcer Prophylaxis: Still a Valid Option in the 1990s?" by Schepp, Vol. 54, pp. 189-99 (1993).
174.	"Prophylactic Therapy for Acute Ulcer Bleeding: A Reappraisal" by Schuman, et al., <u>Ann. Intern. Med.</u> , Vol. 106, pp. 562-67 (1987).
175.	"Stress Ulcer Prophylaxis: In Whom? With What?" by Schuster, <u>Critical Care Medicine</u> , Vol. 21, pp. 4-6 (1993).
176.	"A Dosage Alternative for H-2 Receptor Antagonists, Continuous-Infusion" by Siepler, <u>Clin. Ther.</u> , Vol. 8, pp. 24-33 (1986).
177.	"Role of Gastric Colonization in the Development of Pneumonia in Critically Ill Trauma Patients" by Simms, et al., <u>J. Trauma</u> , Vol. 31, pp. 531-36 (1991).
178.	"Respiratory Failure, Hypotension, Sepsis and Jaundice: A Clinical Syndrome Associated With Lethal..." by Skillman, et al., <u>Am. J. Surg.</u> , Vol. 117, pp. 523-30 (1969).
179.	"The Gastric Mucosal Barrier: Clinical and Experimental Studies In Critically Ill and Normal Man..." by Skillman, et al., <u>Ann. Surg.</u> , Vol. 172, pp. 564-84 (1970).
180.	"Changing Perspectives of Stress Gastritis Prophylaxis" by Smythe & Zarowitz, <u>Ann. Pharmacother.</u> , Vol. 28, pp. 1073-84 (1994).
181.	"Thrombocytopenia Associated With Rantidine" by Spychal & Wickman, <u>Br. Med. J.</u> , Vol. 291, p. 1687 (1985).
182.	"Stress Ulcer Prophylaxis - Quo Vadis?" by Tryba, <u>Intens. Care Med.</u> , Vol. 20, pp. 311-13 (1994).
183.	"Risk of Acute Stress Bleeding and Nosocomial Pneumonia in Ventilated Intensive Care Patients. Sucralfate vs. Antacids" by Tryba, <u>Am. J. Med.</u> , Vol. 87 (3B) 117-24 (1987).
184.	"Side Effects of Ranitidine" by Vial, et al., <u>Drug Saf.</u> , Vol. 6, pp. 94-117 (1991).
185.	"The Relationship Between Gastric Acid Secretion and Gastric H+/K+-ATPase Activity" by Wallmark, et al., <u>J. Biol. Chem.</u> , Vol. 260, pp. 13681-84 (1985).
186.	"Tolerance During Dosing with H2 Receptor Antagonists: An Overview" by Wilder-Smith & Merki, <u>Scand. J. Gastroenterol.</u> , Vol. 27, Suppl. 193, pp. 14-19 (1992).
187.	"The Prevention of Gastro-Intestinal Tract Bleeding in Patients in an Intensive Care Unit" by Zinner, et al., <u>Surg. Gynecol. Obstet.</u> , Vol. 153, pp. 214-20 (1981).
188.	"Influence of Insulin Antibodies on Pharmacokinetics and Bioavailability of Recombinant Human..." by Gray, et al., <u>British Med. J.</u> , Vol. 290, pp. 1687-90 (1985).
189.	"Nasogastric Administration of Omeprazole for Control of Gastric pH" by M. Carroll, et al., <u>10th World Congresses of Gastroenterology</u> , Abstracts (October 2-7, 1994).
190.	"A Lansoprazole Suspension Formulation As An Alternative to Capsules for Oral Administration" by S. Lockhart, et al., <u>World Congresses of Gastroenterology</u> , Abstract Exh A2074 (September 6-11, 1998).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,201
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

191.	"Gastric Acid Antisecretory Effect of Two Different Dosage Forms of Omeprazole During Prolonged Oral Treatment in the Qastric Fistula Dog" by Larsson, et al., Vol. 23, No. 8, pp. 1013-19 (1988).
192.	"Effect of Various Salts on the Stability of Lansoprazole, Omeprazole, and Pantoprazole as Determined by High-Performance Liquid Chromatography" by A. Ekpe, et al., <u>Drug Development and Industrial Pharmacy</u> , Vol. 25, No. 9, pp. 1057-1065 (1999).
193.	"Inhibition of Gastric Secretion by Omeprazole and Efficacy of Calcuim Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis" by Sechet, et al., <u>Nephrologie</u> , Vol. 20, No. 4, pp. 213-16 (1999).
194.	"Role of the Time of Administration of Calcium Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis" by Sechet, et al., <u>Nephrologie</u> , Vol. 20, No. 4, pp. 209-12 (1999).
195.	Onset of Action of Antisecretory Drugs: Beneficial Effects of a Rapid Increase in Intragastric pH in Acid Reflux Disease" by Pipkin, et al., <u>Scand. J. Gastroenterol. Supp.</u> , Vol. 230, pp. 3-8 (1999).
196.	"Omeprazole Disposition in Humans" by Regardh, et al., <u>Ther. Drug Monit.</u> , Vol. 12, No. 2, pp. 165 (1990).
197.	"Evaluation of Buffering Capacity and Acid Neutralizing pH Time Profile of Antacids" by M. Lin, et al., <u>J Formos Med Assoc</u> , Vol. 97, No. 10, pp. 704-710 (1998).
198.	"A Study of Antacid Buffers: I. The Time Factor in Neutralization of Gastric Acidity", by J. Holbert, et al., <u>Journal of The American Pharmaceutical Association (Scientific Edition)</u> , Vol. 36, pp. 149-151 (1947).
199.	"Buffered and Isotonic Solutions", <u>Physical Pharmacy</u> , Chapter 8, pp. 169-189.
200.	"Influence of Insulin Antibodies on Pharmacokinetics and Bioavailability of Recombinant Human..." by Gray, et al., <u>British Medical Journal</u> , 290: 1687-1690 (1985).
201.	"Inhibition of Basal and Betazole - and Sham-Feeding-Induced Acid Secretion by Omeproazole in Man" by Lind, et al., <u>Scand. J. Gastroenterol.</u> , 21:1004-1010 (1986).
202.	"Lansoprazole: Phase I Study of Lansoprazole (AG-1749) Antiulcer Agent (Tablet Form)" by A. Nakagawa, et al., pp. 33-34 (1991).
203.	"Pantoprazole Bicarbonate Suspension (PBS) Provides Oral Bioavailability Comparable To Tablet" by J. Paul, et al., <u>Critical Care Medicine</u> , (Feb. 2001).
204.	<u>Physical Pharmacy - Physical Chemicals Principles in the Pharmaceutical Sciences</u> , Fourth Edition, by A. Martin, et al. (1993).
205.	"Journal of Clinical Therapeutics & Medicines" by Nakagawa, et al., Vol. 7, No. 1, pp. 33-50 (1191).
206.	Organic Chemistry by Wade, Pritice-Hall, Inc., p. 349 (1987).
207.	"The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube" by J. Whipple, et al., Vol. 28, No. 1 (Suppl), p. A69 (January 1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)

Form PTO - 1449 (Modified)

FQRM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,201
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

208.	"High Acid Buffering Capacity of Protein Hydrolysate Infant Formulas" by I. Korponay-Szabo, et al., <u>Journal of Pediatric Gastroenterology and Nutrition</u> , Vol. 31, Supplement 2, Abstract 956 (August 5-9, 2000).
209.	"Esomeprazole" by C. Spencer, et al., <u>Drugs 2000</u> , Vol. 60, No. 2, pp. 321-329 (August 2000).
210.	"Zollinger-Ellison Syndrome - Clinical Presentation in 261 Patients" by P. Roy, et al., <u>Medicine</u> , Vol. 79, No. 6, pp. 379-411 (2000).
211.	"Overuse of Proton Pump Inhibitors" by M. Naunton, et al., <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 25, pp. 333-340 (2000).
212.	"The Proton-Pump Inhibitors: Similarities and Differences" by J. Horn, <u>Clinical Therapeutics</u> , Vol. 22, No. 3, pp. 266-280 (2000).
213.	"Pantoprazole: A New Proton Pump Inhibitor" by P. Jungnickel, <u>Clinical Therapeutics</u> , Vol. 22, No. 11, pp. 1268-1293 (2000).
214.	"Rabeprazole for the Prevention of Pathologic and Symptomatic Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease" by A. Caos, et al., <u>The American Journal of Gastroenterology</u> , Vol. 95, No. 11, pp. 3081-3088 (2000).
215.	"The Stability of Simplified Omeprazole Suspension (SOS)" by J. Phillips, et al., <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), pg. A101, No. 221 (1998).
216.	"A Multicenter Prospective, Randomized Clinical Trial of Continuous Infusion I.V. Ranitidine vs. Omeprazole Suspension in The Prophylaxis of Stress Ulcers" by J. Phillips, et al., <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), pg. A101, No. 222 (1998).
217.	(Deleted)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)
DATE: July 11, 2001 SHEET _11_ of _14_

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

U.S. PATENT DOCUMENTS

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FQRM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT								APPLICANT J. Phillips		
(Use several sheets if necessary) (37 CFR 1.98 (b))								FILING DATE January 11, 2000	GROUP 1625	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER							PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
												YES	NO
238.	0	0	0	5	1	2	9	10/31/79	EPO A1 & B1				
239.	0	2	4	4	3	8	0	11/04/87	EPO A2 & B1				
240.	0	2	4	7	9	8	3	12/02/87	EPO A2 & B1				
241.	0	3	0	8	5	1	5	03/29/89	EPO A1 & B1				
242.	0	3	1	5	9	6	4	05/17/89	EPO A1 & B1				
243.	0	3	9	4	4	7	1	10/31/90	EPO A1				
244.	0	0	4	0	6	3	9	12/02/81	EPO A1 & B1				
245.	0	4	1	4	8	4	7	03/06/91	EPO B1				
246.	0	4	3	6	6	2	0	07/17/91	EPO B1				
247.	0	4	5	2	6	9	7	10/23/91	EPO A1 & B1				
248.	0	4	6	5	2	5	4	01/08/92	EPO A1				
249.	0	4	9	6	4	3	7	07/29/92	EPO A2, B1 & A3				
250.	0	5	0	2	5	5	6	09/09/92	EPO A1 & B1				
251.	0	5	6	5	2	1	0	10/13/93	EPO A2, A3 & B1				
252.	0	5	6	7	2	0	1	10/27/93	EPO A2, A3 & B1				
253.	0	5	6	7	6	4	3	11/03/93	EPO A1				
254.	0	5	8	7	6	5	9	03/23/94	EPO B1				
255.	0	6	5	2	7	5	1	05/17/95	EPO B1				
256.	0	6	9	6	9	2	1	02/21/96	EPO B1				
257.	0	2	0	2	2	2	5	01/25/90	JP				
258.	0	3	0	3	4	9	6	02/14/91	JP				
259.	0	3	0	4	8	6	8	03/01/91	JP				
260.	0	3	0	5	2	8	8	03/07/91	JP				
261.	0	5	1	1	7	2	6	05/14/93	JP				
262.	0	5	1	9	4	2	2	08/03/93	JP				
263.	0	5	2	5	5	0	8	10/05/93	JP/English Trans. Attached				
264.	0	5	2	9	4	8	3	11/09/93	JP/English Trans. Attached				
265.	0	6	0	9	2	8	5	04/05/94	JP				
266.	0	6	1	0	0	4	4	04/12/94	JP				
267.	0	7	0	3	3	6	5	02/03/95	JP				
268.	0	9	0	8	7	1	1	03/31/97	JP				
269.	1	0	0	1	7	4	7	01/20/98	JP				
270.	1	0	0	1	7	4	7	01/20/98	JP				
271.	4	8	1	0	3	5	6	12/25/73	JP				
272.	4	9	0	0	5	9	6	01/19/74	JP				
273.	4	9	0	1	3	1	7	02/05/74	JP				
274.	4	9	0	2	0	1	7	02/22/74	JP				
275.	4	9	0	2	0	1	7	02/22/74	JP				
EXAMINER								DATE CONSIDERED					

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT								APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))								FILING DATE January 11, 2000	GROUP 1625

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER							PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
												YES	NO
276.	4	9	0	9	3	5	3	7	09/05/74	JP			
277.	4	9	0	9	5	9	9	7	09/11/74	JP			
278.	5	0	0	5	2	0	6	5	05/09/75	JP			
279.	5	0	1	1	2	3	7	3	09/03/75	JP			
280.	5	0	1	4	2	5	6	5	11/17/75	JP			
281.	5	1	0	1	6	6	6	9	02/10/76	JP			
282.	5	1	0	1	7	2	6	8	08/27/77	JP			
283.	5	1	1	3	1	8	7	5	11/16/76	JP			
284.	5	2	0	0	5	7	6	9	01/17/77	JP			
285.	5	2	0	1	4	7	7	6	02/03/77	JP			
286.	5	2	0	9	7	9	7	8	08/17/77	JP			
287.	5	3	0	5	9	6	7	5	05/29/78	JP			
288.	5	5	0	1	9	2	1	1	02/09/80	JP			
289.	5	6	0	6	1	3	1	1	05/26/81	JP			
290.	5	9	0	9	5	9	9	7	06/02/84	JP			
291.	6	1	2	2	1	1	1	7	10/01/86	JP			
292.	6	2	1	4	5	0	8	3	06/29/87	JP			
293.	6	2	2	5	8	3	1	6	11/10/87	JP			
294.	6	2	2	5	8	3	2	0	11/10/87	JP			
295.	6	2	2	7	7	3	2	2	12/02/87	JP/English Trans. Attached			
296.	7	0	0	3	9	5	4	1	12/12/70	JP			
297.	7	0	0	3	9	5	4	3	12/12/70	JP			
298.	7	1	0	0	9	5	8	0	03/11/71	JP			
299.	7	1	0	0	9	5	8	1	03/11/71	JP			
300.	7	4	0	4	1	1	9	8	11/07/74	JP			
301.	8	0	0	1	9	2	1	1	05/24/80	JP			
302.	200	0	2	1	2	1	8	0	08/02/00	JP			
303.	8	9	0	0	5	6	6		01/26/89	WO A1			
304.	9	2	0	4	8	9	8		04/02/92	WO A1			
305.	9	2	0	8	7	1	6		05/29/92	WO A1			
306.	9	3	0	5	7	7	0		04/01/93	WO A1			
307.	9	4	0	2	1	4	1		02/03/94	WO A1			
308.	9	5	0	1	7	8	3		01/19/95	WO A1			
309.	9	5	0	7	9	1	3		03/23/95	WO A1			
310.	9	5	1	5	9	6	2		06/15/95	WO A1			
311.	9	5	2	3	5	9	4		09/08/95	WO A1			
312.	9	5	3	2	9	5	8		12/07/95	WO A1			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE									ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT									APPLICANT J. Phillips			
(Use several sheets if necessary) (37 CFR 1.98 (b))									FILING DATE January 11, 2000	GROUP 1625		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER								PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION		
													YES	NO	
313.	9	5	3	2	9	5	9	12/07/95	WO A1						
314.	9	6	0	1	6	2	5	01/25/96	WO A1						
315.	9	6	1	6	9	5	9	06/06/96	WO A1						
316.	9	6	3	8	1	7	5	12/05/96	WO A1						
317.	9	7	0	9	9	6	4	03/20/97	WO A1						
318.	9	7	2	5	0	6	4	07/17/97	WO A1						
319.	9	7	2	5	0	6	6	07/17/97	WO A1						
320.	9	8	1	6	2	2	8	04/23/98	WO A1						
321.	9	8	4	0	0	5	4	09/17/98	WO A1						
322.	9	9	4	5	0	0	4	09/10/99	WO A1						
323.	9	9	5	5	7	0	5	11/04/99	WO A1						
324.	9	9	5	5	7	0	6	11/04/99	WO A1						
325.	0	0	1	0	9	9	9	03/02/00	WO A2 & A3						
326.	0	0	2	7	3	6	6	05/18/00	WO A1						
327.	0	0	2	8	9	7	5	05/25/00	WO A2 & A3						
328.	0	0	3	0	6	1	2	06/02/00	WO A1						
329.	0	0	3	5	4	4	8	06/22/00	WO A1						
330.	0	0	4	4	7	4	4	08/03/00	WO A1						
331.	0	0	4	5	8	1	7	08/10/00	WO A1						
332.	0	0	6	9	4	3	8	11/23/00	WO A1						
333.	0	0	7	8	2	9	3	12/28/00	WO A1						

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)